Johnson & Johnson's earnings call highlighted continued strong performance, exceeding expectations in adjusted earnings and sales, despite some headwinds.  Management expressed confidence in all three segments, particularly the Medical Device and Consumer businesses, which are projected for above-market growth in 2017.  The call also included discussions about potential divestitures and capital allocation strategies, including potential acquisitions.  Short-term, positive momentum fueled by strong performance, especially in pharmaceuticals, with a cautious outlook for REMICADE.


[1]
